Successful treatment of Behçet’s uveitis with Tocilizumab

A 33-year-old man with history of lymphoma was misdiagnosed as multiple sclerosis (MS) 18 months previously, developed intermediate uveitis, unresponsive to interferon, and corticosteroids. A diagnosis of Behçet’s disease (BD) was made on the basis of recurrent orogenital ulceration, erythema nodosu...

Descripción completa

Detalles Bibliográficos
Autores principales: Alokaily, F., Al Saati, A., Jawad, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352938/
https://www.ncbi.nlm.nih.gov/pubmed/28337062
http://dx.doi.org/10.1016/j.sjopt.2016.12.004
_version_ 1782515060844789760
author Alokaily, F.
Al Saati, A.
Jawad, A.
author_facet Alokaily, F.
Al Saati, A.
Jawad, A.
author_sort Alokaily, F.
collection PubMed
description A 33-year-old man with history of lymphoma was misdiagnosed as multiple sclerosis (MS) 18 months previously, developed intermediate uveitis, unresponsive to interferon, and corticosteroids. A diagnosis of Behçet’s disease (BD) was made on the basis of recurrent orogenital ulceration, erythema nodosum, and a positive pathergy test. The patient was started on Tocilizumab and experienced an improvement in visual acuity and intraocular inflammation over the following 2 weeks. In patients with BD-related uveitis, Tocilizumab can be an effective alternative to anti-tumor necrosis factor alpha medications.
format Online
Article
Text
id pubmed-5352938
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-53529382017-03-23 Successful treatment of Behçet’s uveitis with Tocilizumab Alokaily, F. Al Saati, A. Jawad, A. Saudi J Ophthalmol Case Report A 33-year-old man with history of lymphoma was misdiagnosed as multiple sclerosis (MS) 18 months previously, developed intermediate uveitis, unresponsive to interferon, and corticosteroids. A diagnosis of Behçet’s disease (BD) was made on the basis of recurrent orogenital ulceration, erythema nodosum, and a positive pathergy test. The patient was started on Tocilizumab and experienced an improvement in visual acuity and intraocular inflammation over the following 2 weeks. In patients with BD-related uveitis, Tocilizumab can be an effective alternative to anti-tumor necrosis factor alpha medications. Elsevier 2017 2016-12-20 /pmc/articles/PMC5352938/ /pubmed/28337062 http://dx.doi.org/10.1016/j.sjopt.2016.12.004 Text en © 2016 Production and hosting by Elsevier B.V. on behalf of Saudi Ophthalmological Society, King Saud University. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Alokaily, F.
Al Saati, A.
Jawad, A.
Successful treatment of Behçet’s uveitis with Tocilizumab
title Successful treatment of Behçet’s uveitis with Tocilizumab
title_full Successful treatment of Behçet’s uveitis with Tocilizumab
title_fullStr Successful treatment of Behçet’s uveitis with Tocilizumab
title_full_unstemmed Successful treatment of Behçet’s uveitis with Tocilizumab
title_short Successful treatment of Behçet’s uveitis with Tocilizumab
title_sort successful treatment of behçet’s uveitis with tocilizumab
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352938/
https://www.ncbi.nlm.nih.gov/pubmed/28337062
http://dx.doi.org/10.1016/j.sjopt.2016.12.004
work_keys_str_mv AT alokailyf successfultreatmentofbehcetsuveitiswithtocilizumab
AT alsaatia successfultreatmentofbehcetsuveitiswithtocilizumab
AT jawada successfultreatmentofbehcetsuveitiswithtocilizumab

Ejemplares similares